Trial Profile

A Phase 3 Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer (MK-3475-C66)

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 25 May 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pembrolizumab (Primary) ; Bevacizumab; Cetuximab; Fluorouracil; Folic acid; Irinotecan; Oxaliplatin
Indications Adenocarcinoma; Colorectal cancer
Focus Registrational; Therapeutic Use
Acronyms MK-3475-C66
Sponsors Merck Sharp & Dohme Corp.

22 May 2026 Status changed from recruiting to active, no longer recruiting.
20 Aug 2024 Planned End Date changed from 10 Nov 2026 to 19 Sep 2028.
20 Aug 2024 Planned primary completion date changed from 10 Nov 2026 to 19 Sep 2028.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com